FOXA1 mutations alter pioneering activity, differentiation, and prostate cancer phenotypes

Mutations in the transcription factor FOXA1 define a unique subset of prostate cancers but the functional consequences of these mutations and whether they confer gain or loss of function is unknown1–9. Here, by annotating the landscape of FOXA1 mutations from 3,086 human prostate cancers, we define two hotspots in the forkhead domain: Wing2 (around 50% of all mutations) and the highly conserved DNA-contact residue R219 (around 5% of all mutations). Wing2 mutations are detected in adenocarcinomas at all stages, whereas R219 mutations are enriched in metastatic tumours with neuroendocrine histology. Interrogation of the biological properties of wild-type FOXA1 and fourteen FOXA1 mutants reveals gain of function in mouse prostate organoid proliferation assays. Twelve of these mutants, as well as wild-type FOXA1, promoted an exaggerated pro-luminal differentiation program, whereas two different R219 mutants blocked luminal differentiation and activated a mesenchymal and neuroendocrine transcriptional program. Assay for transposase-accessible chromatin using sequencing (ATAC-seq) of wild-type FOXA1 and representative Wing2 and R219 mutants revealed marked, mutant-specific changes in open chromatin at thousands of genomic loci and exposed sites of FOXA1 binding and associated increases in gene expression. Of note, ATAC-seq peaks in cells expressing R219 mutants lacked the canonical core FOXA1-binding motifs (GTAAAC/T) but were enriched for a related, non-canonical motif (GTAAAG/A), which was preferentially activated by R219-mutant FOXA1 in reporter assays. Thus, FOXA1 mutations alter its pioneering function and perturb normal luminal epithelial differentiation programs, providing further support for the role of lineage plasticity in cancer progression.Mutations in the transcription factor FOXA1 that are common in prostate cancer result in gain-of-function effects that promote changes in the differentiation of tumour cells.

[1]  Matti Nykter,et al.  Frequent mutation of the FOXA1 untranslated region in prostate cancer , 2018, Communications Biology.

[2]  William Stafford Noble,et al.  FIMO: scanning for occurrences of a given motif , 2011, Bioinform..

[3]  Jan Komorowski,et al.  Differential binding and co-binding pattern of FOXA1 and FOXA3 and their relation to H3K4me3 in HepG2 cells revealed by ChIP-seq , 2009, Genome Biology.

[4]  Steven J. M. Jones,et al.  The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.

[5]  N. Schultz,et al.  ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis , 2017, Nature.

[6]  Matteo Benelli,et al.  Divergent clonal evolution of castration resistant neuroendocrine prostate cancer , 2016, Nature Medicine.

[7]  N. Socci,et al.  Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor , 2010, Proceedings of the National Academy of Sciences.

[8]  B. Trock,et al.  Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men. , 2016, European urology.

[9]  Yi Mi Wu,et al.  The long tail of oncogenic drivers in prostate cancer , 2018, Nature Genetics.

[10]  W. Peng,et al.  Epithelial cell-targeted transgene expression enables isolation of cyan fluorescent protein (CFP)-expressing prostate stem/progenitor cells , 2011, Transgenic Research.

[11]  Lior Pachter,et al.  Near-optimal probabilistic RNA-seq quantification , 2016, Nature Biotechnology.

[12]  Björn Usadel,et al.  Trimmomatic: a flexible trimmer for Illumina sequence data , 2014, Bioinform..

[13]  R. Schiff,et al.  FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer , 2019, Proceedings of the National Academy of Sciences.

[14]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.

[15]  Anirban P. Mitra,et al.  Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. , 2013, The Journal of urology.

[16]  R. D. del Rosario,et al.  DNA-mediated dimerization on a compact sequence signature controls enhancer engagement and regulation by FOXA1 , 2018, Nucleic acids research.

[17]  Joshua M. Stuart,et al.  A basal stem cell signature identifies aggressive prostate cancer phenotypes , 2015, Proceedings of the National Academy of Sciences.

[18]  Solomon H. Snyder,et al.  Erratum: Inositol polyphosphate multikinase is a coactivator of p53-mediated transcription and cell death (Science Signaling (2013) 6: 273 (er1) Doi: 10.1126/scisignal.6273er1) , 2013 .

[19]  Zachary J. Heins,et al.  Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. , 2017, JCO precision oncology.

[20]  Wei Li,et al.  RSeQC: quality control of RNA-seq experiments , 2012, Bioinform..

[21]  O. Gileadi,et al.  The crystal structure of human forkhead box N1 in complex with DNA reveals the structural basis for forkhead box family specificity , 2019, The Journal of Biological Chemistry.

[22]  Glen Kristiansen,et al.  Tumorigenesis and Neoplastic Progression FOXA 1 Promotes Tumor Progression in Prostate Cancer and Represents a Novel Hallmark of Castration-Resistant Prostate Cancer , 2012 .

[23]  G. Jenster,et al.  Identification of TDRD1 as a direct target gene of ERG in primary prostate cancer , 2013, International journal of cancer.

[24]  Jindan Yu,et al.  Androgen receptor-independent function of FoxA1 in prostate cancer metastasis. , 2013, Cancer research.

[25]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[26]  Trevor J Pugh,et al.  Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer , 2020, Nature Communications.

[27]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[28]  Henry W. Long,et al.  The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis , 2015, Nature Genetics.

[29]  E. Cuppen,et al.  Identification of Multipotent Luminal Progenitor Cells in Human Prostate Organoid Cultures , 2014, Cell.

[30]  C. Sander,et al.  Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets , 2018, Nature Genetics.

[31]  F. Feng,et al.  Genomic Prostate Cancer Classifier Predicts Biochemical Failure and Metastases in Patients After Postoperative Radiation Therapy , 2014, International journal of radiation oncology, biology, physics.

[32]  Wei Wang,et al.  FOXA1 Suppresses the Growth, Migration, and Invasion of Nasopharyngeal Carcinoma Cells through Repressing miR-100-5p and miR-125b-5p , 2020, Journal of Cancer.

[33]  Anirban P. Mitra,et al.  Discovery and Validation of a Prostate Cancer Genomic Classifier that Predicts Early Metastasis Following Radical Prostatectomy , 2013, PloS one.

[34]  M. Rubin,et al.  SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling. , 2017, Cancer cell.

[35]  E. Lander,et al.  Genetic Screens in Human Cells Using the CRISPR-Cas9 System , 2013, Science.

[36]  A. Snowman,et al.  Inositol Polyphosphate Multikinase Is a Coactivator of p53-Mediated Transcription and Cell Death , 2013, Science Signaling.

[37]  A. Sivachenko,et al.  Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer , 2012, Nature Genetics.

[38]  H. Clevers,et al.  Controlled gene expression in primary Lgr5 organoid cultures , 2011, Nature Methods.

[39]  R. Caprioli,et al.  Forkhead box A1 regulates prostate ductal morphogenesis and promotes epithelial cell maturation , 2005, Development.

[40]  M. Kattan,et al.  A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy. , 2015, European urology.

[41]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[42]  Mikael Bodén,et al.  MEME Suite: tools for motif discovery and searching , 2009, Nucleic Acids Res..

[43]  Yong Zhang,et al.  Identifying ChIP-seq enrichment using MACS , 2012, Nature Protocols.

[44]  Jonathan E. Shoag,et al.  Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer , 2018, JCO precision oncology.

[45]  C. Sander,et al.  Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis , 2009, Nature Genetics.

[46]  E. Fuchs,et al.  Actin cable dynamics and Rho/Rock orchestrate a polarized cytoskeletal architecture in the early steps of assembling a stratified epithelium. , 2002, Developmental cell.

[47]  Kate B. Cook,et al.  Determination and Inference of Eukaryotic Transcription Factor Sequence Specificity , 2014, Cell.

[48]  M. Schmitt-Ney.  The FOXO’s Advantages of Being a Family: Considerations on Function and Evolution , 2020, Cells.

[49]  Steven J. M. Jones,et al.  Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer , 2015, Cell.

[50]  Steven L Salzberg,et al.  Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.

[51]  Lawrence D. True,et al.  Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.

[52]  T. Golub,et al.  Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. , 2006, Cancer cell.

[53]  Peter J. Bickel,et al.  Measuring reproducibility of high-throughput experiments , 2011, 1110.4705.

[54]  Benjamin J. Raphael,et al.  The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2016 .

[55]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.